Over twenty years experience in a lead position in oncology drug discovery programs on protein-drug conjugates and signal transduction inhibitors with expertise in protein purification, protein characterization, HPLC, cell culture and assay development. Additional experience in antibiotics, inflammation and allergy. Managed associates in both academic and industrial positions. Experienced in directing an individual laboratory as part of a multidisciplinary approach to long and short term goals. Presently in leadership position as vice-president of R & D of Lauren Sciences LLC developing drugs for brain diseases using its platform for crossing the blood-brain barrier.. Numerous patents on immunoconjugates resulting in leukemia drug Mylotarg. Developed patented method to prevent aggregation during and after conjugation. Involved in early work on irreversible inhibitors of Her family kinases resulting in EKB and HKI (neratinib) which are undergoing clinical testing. Developed technique to distinguish reversible from irreversible tight-binding inhibitors that led to the drugs presently in clinical testing. Recently was in a senior position in a PI3K inhibitor program from its conception to approved INDs for one oral and one i.v. drug. Expression, purification, stabilization, and homogeneous HTS assays for PI3K alpha and gamma were all developed within the group.Specialties: drug discoveryprotein purificationcell cultureprotein stabilityassay developmentdrug delivery